Of note, ensifentrine reduces exacerbations in COPD trial populations, and whether this relates to either PDE3 and/or PDE4 inhibitory activities remains unclear, as does the therapeutic potential for ensifentrine in exacerbation-prone COPD patients [105]. Here, PDE4A is linked to chronic obstructive pulmonary disease.